NCT06157892 2026-03-17A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsSeagen Inc.Phase 2 Recruiting172 enrolled
NCT04430738 2026-02-24Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersSeagen Inc.Phase 2 Active not recruiting40 enrolled 67 charts
NCT03043313 2024-11-26Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerSeagen Inc.Phase 2 Completed117 enrolled 21 charts 1 FDA
NCT05190445 2022-09-08Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ AndenocarinomaPieris Pharmaceuticals, Inc.Phase 2 Active not recruiting80 enrolled